Perceptive Advisors LLC Has $114.76 Million Holdings in Inhibrx Biosciences, Inc. $INBX

Perceptive Advisors LLC increased its holdings in Inhibrx Biosciences, Inc. (NASDAQ:INBX) by 9.4% in the fourth quarter, Holdings Channel reports. The institutional investor owned 1,452,707 shares of the company’s stock after buying an additional 125,000 shares during the period. Inhibrx Biosciences makes up 2.0% of Perceptive Advisors LLC’s holdings, making the stock its 11th largest holding. Perceptive Advisors LLC owned about 0.10% of Inhibrx Biosciences worth $114,764,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Schonfeld Strategic Advisors LLC raised its position in shares of Inhibrx Biosciences by 120.5% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 214,725 shares of the company’s stock valued at $16,963,000 after buying an additional 117,343 shares in the last quarter. AQR Capital Management LLC raised its position in shares of Inhibrx Biosciences by 25.1% in the fourth quarter. AQR Capital Management LLC now owns 7,501 shares of the company’s stock valued at $593,000 after buying an additional 1,503 shares in the last quarter. Jain Global LLC acquired a new stake in shares of Inhibrx Biosciences in the fourth quarter valued at approximately $956,000. Laird Norton Wetherby Trust Company LLC acquired a new stake in shares of Inhibrx Biosciences in the fourth quarter valued at approximately $3,190,000. Finally, Jump Financial LLC acquired a new stake in shares of Inhibrx Biosciences in the fourth quarter valued at approximately $277,000. 82.46% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on INBX shares. Lifesci Capital upgraded shares of Inhibrx Biosciences to a “strong-buy” rating in a research report on Friday, April 24th. Zacks Research upgraded shares of Inhibrx Biosciences to a “hold” rating in a research report on Thursday, April 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inhibrx Biosciences in a research report on Tuesday. Stifel Nicolaus started coverage on shares of Inhibrx Biosciences in a research report on Wednesday, April 8th. They issued a “buy” rating and a $150.00 price target for the company. Finally, Wall Street Zen upgraded shares of Inhibrx Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, June 13th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $150.00.

Inhibrx Biosciences Stock Up 1.2%

Shares of INBX opened at $94.20 on Thursday. Inhibrx Biosciences, Inc. has a one year low of $13.97 and a one year high of $155.29. The company has a market cap of $1.38 billion, a P/E ratio of -11.23 and a beta of 3.31. The company has a debt-to-equity ratio of 12.58, a current ratio of 6.46 and a quick ratio of 6.46. The firm has a 50 day simple moving average of $102.15 and a two-hundred day simple moving average of $85.25.

Inhibrx Biosciences (NASDAQ:INBX) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($2.15) EPS for the quarter, missing the consensus estimate of ($1.68) by ($0.47). Research analysts forecast that Inhibrx Biosciences, Inc. will post -10.15 EPS for the current fiscal year.

Inhibrx Biosciences Company Profile

Inhibrx, Inc, headquartered in La Jolla, California, is a clinical-stage biotechnology company focused on the discovery and development of next-generation protein therapeutics. The company’s proprietary protein engineering platform enables the design and production of multispecific and multivalent biologics with tailored binding characteristics and favorable pharmacokinetic properties. By leveraging high-throughput screening and structure-based design, Inhibrx aims to create molecules that address challenging targets in oncology, regenerative medicine and other areas of unmet medical need.

The company’s lead candidate, INBRX-109, is a tetravalent agonist of the receptor tyrosine kinase ROR2 designed to stimulate tissue repair and regeneration.